Form 4: Intellia Director William Chase Receives Equity Grant

Intellia Therapeutics director William J. Chase was granted 9,200 restricted stock units and 13,300 stock options on June 9, 2026.

Summary

• Director William J. Chase acquired 9,200 shares of common stock via restricted stock units (RSUs).
• Director William J. Chase was granted 13,300 stock options with an exercise price of $12.89.
• The total beneficial ownership for the director following these transactions is 143,893 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard annual equity grant for board service.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Market volatility affecting the value of granted equity.
• Performance risk associated with the underlying business of Intellia Therapeutics.

Future Outlook

The stock options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board retention and alignment with long-term corporate milestones.

Comparison to Industry Standards

• The grant structure is consistent with standard compensation packages for directors in mid-cap biotech firms.
• Vesting schedules align with typical one-year annual meeting cycles observed in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of the granted stock options on the earlier of June 9, 2027, or the next annual meeting.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, Insider Trading, Equity Compensation, Biotech